Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.

Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting.

About the Boceprevir HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). SVR rates are not yet available for Part II of this study evaluating boceprevir with low-dose REBETOL (n=59) compared to contemporaneous control (n=16) as described above.

About Boceprevir Phase III Studies

Schering-Plough is conducting two large ongoing pivotal Phase III studies of boceprevir in patients chronically infected with HCV genotype 1. One study is in treatment-naive patients and the other in patients who failed prior treatment (relapsers and nonresponders). The two randomized, double-blind, placebo-controlled studies evaluate the efficacy of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SAN DIEGO, Feb. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... patient enrollment in its bioequivalence study of ANX-514 (docetaxel ... announce results from this study in the second quarter ... chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved ...
... to monitor health outcomes in Fresno, California LOS ALTOS, ... Foundation (GHRF) today announced that it has received a ... treatment in California,s Central Valley, a region with the ... grant will help fund data collection and analysis at ...
Cached Medicine Technology:ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 2ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 3Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2
(Date:7/13/2014)... in The Lancet Neurology calls for ... term neurological problems that repeated concussions can cause. ... of sports-related traumatic brain injury (TBI), and the ... amyotrophic lateral sclerosis, and other neurological disorders, say ... concerning, is that even when the symptoms of ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... portable, microchip-based test for diagnosing type-1 diabetes could ... understand the disease, according to the device,s inventors ... Described in a paper to be published online ... test employs nanotechnology to detect type-1 diabetes outside ... two main forms of diabetes mellitus, which are ...
(Date:7/13/2014)... Victorian Hotel has recently announced that it ... bikes for its "Cycle the City" program, which encourages ... the area using a rental bicycle, available for just ... call Vancouver home, as it is a city with ... journeys through the countryside. Vancouver hotel rooms often play ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... high health-care costs it has become a burden both on ... as a respite comes a new cardio drug that negates ... ,The drug is in the African-American heart failure patients where ... Angus, M.D., M.P.H., professor of critical care medicine at the ...
... A liver transplant operation has been conducted on a six-year-old ... underwent the surgery celebrates his birthday on 19 December 2005. ... 'The kid is still in ICU but is responding well ... hope his condition will be normal soon.' , ,He ...
... Clinic say that the flagship breast cancer drug, tamoxifen might ... genetic variation. // ,This particular variant gene has the ... is vital to activate tamoxifen against breast cancer. The study ... of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an ...
... is responsible for the death of Rene Anderson, a diabetic ... was prescribed to Mrs. Anderson to ease the numbness and ... // ,The medicine is reported to have resulted disturbed ... an intoxicated and confused state. Here her condition continued to ...
... formed a new cabinet committee to plan strategies to fight ... said that though the United Kingdom //Government has taken various ... spread but the committee feels still a lot has to ... committee feels that the Government should organize the food sector ...
... easily subsided by administering sweet to children now has a ... ,They have reported that the analgesic efficacy of sweet ... sweet taste and by the child's weight status. This appears ... just because they taste good, but also because sweets make ...
Cached Medicine News:Health News:A cost effective heart failure drug hits the market! 2Health News:Sweet pain releiver! 2
... Workstations provide comprehensive neurological monitoring in ... unit to accurately access your patients ... 15 years experience, and a long ... neurological monitoring systems have a proven ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... system especially designed for surgical monitoring and ... channels and is equipped with two headboxes ... can be independently configured as either a ... Endeavor amplifiers are based on the Firewire ...
Medicine Products: